Form 4 Filing for Edgewise Therapeutics, Inc.

This filing reports a Form 4 for Edgewise Therapeutics, Inc. (EWTX) concerning transactions by director Christopher Nathan Martin. On June 5, 2026, Mr. Martin acquired 16,377 stock options with a purchase price of $0.00 per share. These options are exercisable at $35.59 per share and will vest on June 5, 2027, or the business day before the 2027 annual meeting, whichever comes first. The options expire on June 5, 2036. Following this transaction, Mr. Martin directly owns 16,377 shares of common stock underlying these options. The filing was signed on June 16, 2026, by an attorney-in-fact.